

# Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

## DERL-2

RRID:CVCL\_2016

Type: Cell Line

---

### Proper Citation

RRID:CVCL\_2016

---

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_2016](https://web.expasy.org/cellosaurus/CVCL_2016)

**Proper Citation:** RRID:CVCL\_2016

**Description:** Cell line DERL-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Hepatosplenic T-cell lymphoma

**Defining Citation:** [PMID:10800166](#), [PMID:11587224](#), [PMID:28122867](#)

**Comments:** Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** DERL-2

**Synonyms:** DERL2, DERL-NK2

**Cross References:** CLO:CLO\_0037049, BioSample:SAMN03473525, cancercellines:CVCL\_2016, Cell\_Model\_Passport:SIDM01509, DepMap:ACH-001057, DSMZ:ACC-531, DSMZCellDive:ACC-531, GEO:GSM1374460, LINCS\_LDP:LCL-1116, Wikidata:Q54830978

**ID:** CVCL\_2016

**Record Creation Time:** 20220427T215816+0000

**Record Last Update:** 20260815T232709+0000

---

## Ratings and Alerts

No rating or validation information has been found for DERL-2.

No alerts have been found for DERL-2.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Ianevski A, et al. (2026) Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery. Cancer research, 86(2), 295.

Gro?? E, et al. (2023) SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters. Cancers, 15(11).

Schleser SW, et al. (2023) Palladium and Platinum Complexes of the Antimetabolite Fludarabine with Vastly Enhanced Selectivity for Tumour over Non-Malignant Cells. Molecules (Basel, Switzerland), 28(13).